Twist Bioscience Corporation (TWST)财务
NASDAQ · Healthcare · Biotechnology · 员工979人 · CEO Emily Marine Leproust
- 股价
- $152.78 -11.92%
- 市值
- $101亿
- 企业价值
- $100亿
- 最近财报
- Q3 '26 2026-08-03提交
- 下次财报
- 2026-11-12 EPS预期 -$0.38
营收(TTM)$4.32亿+19.2% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)-31.9%+7.4 百分点 对比去年同期营业利润 -$1.38亿
净利润(TTM)-$1.37亿-60.5% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$9310万-35.5% 对比去年同期资本支出 $4010万
稀释EPS(TTM)-$2.22-52.1% 对比去年同期最近4个季度之和
净现金$7320万-57.6% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $101亿 EV $100亿
- 营收
- $4.32亿 过去12个月
- 营收增速
- +21% FY2026年一致预期
- 净利润率
- -31.7% 净利润 / 营收,TTM
- P/E
- -68.8× 预期 -71.3×(FY2026)
- P/S
- 23.3× 股价 / 营收,TTM
- EV / EBITDA
- -93.1× TTM
- 自由现金流
- -$9310万 过去12个月
- 净利润
- -$1.37亿 过去12个月
- 营收预期
- $4.56亿 FY2026年一致预期
- 盈利
- 2026-11-12 营收预期 $1.24亿
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-03):营收超预期3.4%,EPS 低于预期10.6%营收$1.18亿,预期$1.15亿(+3.4%);EPS -$0.56,预期-$0.51(-10.6%)。
- 营收增长加速:同比23.2%Q3 '26营收$1.18亿,此前四个季度的平均值为17.7%。
- 营业利润率-31.9%(TTM),较去年同期+7.4 百分点营收增长19.2%,营业利润增长3.2%。
- 资本支出占营收的9.3%(去年为4.9%)最近4个季度投入$4010万(同比+127.8%)。自由现金流-$9310万。
- 稀释股数一年内增加2.0%Q3 '26稀释股数6240万,一年前为6120万。
- 净现金 $7320万现金 + 短期投资 $1.67亿,含租赁债务 $9360万;一年前净现金 $1.73亿。
上一季度:Q3 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $1.18亿 | $9610万 | +23.2% |
| 毛利率 | 52.8% | 53.4% | -0.6 百分点 |
| 营业利润 | -$3630万 | -$3010万 | -20.5% |
| 营业利润率 | -30.6% | -31.4% | +0.7 百分点 |
| 净利润 | -$3510万 | $2040万 | -271.9% |
| 稀释EPS | -$0.56 | $0.33 | -269.7% |
| 经营现金流 | $112万 | -$140万 | +179.6% |
| 资本支出 | $966万 | $917万 | +5.4% |
| 自由现金流 | -$855万 | -$1060万 | +19.1% |
| R&D | $1800万 | $1800万 | -0.1% |
| 股权激励费用 | $1820万 | $1610万 | +13.2% |
实际 vs 一致预期
2026-08-03| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $1.18亿 | $1.15亿 | +3.4% |
| EPS(一致预期口径) | -$0.56 | -$0.51 | -10.6% |
来自2026-08-03发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Ngs Tools | $6180万 | +11.8% | 52.2% | $2.25亿 | +12.1% | |
| Antibody Discovery | $5660万 | +907.7% | 47.8% | $1.67亿 | +650.2% | |
| Synthetic Genes | – | – | – | – | – | |
| Oligo Pools | – | – | – | – | – | |
| Dna And Biopharma Libraries | – | – | – | – | – |
按地区划分的营收
占总额比例| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Americas | $7730万 | +30.1% | 65.3% | $2.57亿 | +16.4% | |
| EMEA | $3360万 | +9.4% | 28.4% | $1.44亿 | +24.9% | |
| Asia Pacific | $750万 | +26.4% | 6.3% | $3070万 | +17.4% |
分部利润
取自每份10-Q / 10-K分部附注的各披露分部营业利润(多数数据源缺少的利润拆分)。
Q3 '26分部
| 分部 | 营收 | 同比 | 营业利润 | 同比 | 利润率 | 去年同期利润率 | TTM营业利润 |
|---|---|---|---|---|---|---|---|
| Reportable Segment | – | – | -$3630万 | -20.5% | – | – | -$1.45亿 |
各分部营业利润
季度各分部营业利润率
季度第四季度为推算值:10-K披露全年数据,减去10-Q的前三个季度。
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$5310万
- 资本支出
- -$4010万
- 股票回购
- -$1.8万
- 股息
- $0
- 收购
- $0
- 债务净发行
- $0
- 股权激励费用
- $6650万
- 自由现金流
- -$9310万
- 股东回报 / FCF
- -0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -68.8× | – | – |
| EV / EBITDA | -93.1× | – | – |
| EV / 营收 | 23.2× | 12.0× | 3.9× – 36.0× |
| 股价 / FCF | -108.0× | – | – |
| 股价 / 净资产 | 21.4× | 4.4× | 1.8× – 8.9× |
| FCF收益率 | -0.9% | -7.3% | -14.8% – -2.6% |
| 投入资本回报率 | -24.6% | -28.5% | -39.6% – -23.2% |
| 净资产收益率 | -29.9% | -29.4% | -44.2% – -16.4% |
分析师
一致目标价 $153.70 (+0.6%)
区间 $89.00 – $215.00 · 评级 Buy
强烈买入0
买入11
持有2
卖出2
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $4.56亿 | +21.2% | -$2.14 | -64.8% | -71.3× | 4 |
| FY2027 | $5.49亿 | +20.2% | -$1.31 | +38.8% | -116.5× | 5 |
| FY2028 | $6.46亿 | +17.7% | -$0.87 | +33.4% | -175.0× | 8 |
| FY2029 | $7.73亿 | +19.8% | -$0.06 | +93.0% | -2,485.2× | 3 |
| FY2030 | $10.1亿 | +30.7% | $0.94 | +1,620.9% | 163.4× | 1 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Twist Bioscience Corporation在近期10-Q / 10-K文件中标记的全部238项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $1700万 | $1200万 | +42.2% | $1110万 | $163万 | +580.6% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $6510万 | $4990万 | +30.5% | $5700万 | $3490万 | +63.4% |
| Accounts Receivable, Allowance for Credit Loss | $60万 | $50万 | +20.0% | $60万 | $70万 | -14.3% |
| Accrued Liabilities, Current | $2050万 | $1950万 | +4.7% | $2310万 | $1510万 | +52.6% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $1.12亿 | $8930万 | +25.1% | $9500万 | $7560万 | +25.6% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$65.5万 | -$86.4万 | +24.2% | -$62.7万 | -$52.2万 | -20.1% |
| Additional Paid in Capital | $18.8亿 | $17.7亿 | +5.9% | $17.9亿 | $17.2亿 | +4.6% |
| Advertising Expense | – | – | – | $700万 | $520万 | +34.6% |
| Amortization of Intangible Assets | $30万 | $30万 | 0.0% | $110万 | $410万 | -73.2% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 606万 | 372万 | +62.8% | 519万 | 509万 | +2.0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $1820万 | $1610万 | +13.1% | $6450万 | $5100万 | +26.5% |
| Asset Impairment Charges | $02025-09-30 | $0 | – | $0 | $4490万 | -100.0% |
| Assets | $6.72亿 | $6.44亿 | +4.5% | $6.42亿 | $6.14亿 | +4.5% |
| Assets, Current | $3.21亿 | $3.4亿 | -5.4% | $3.33亿 | $3.47亿 | -4.0% |
| Assets, Fair Value Disclosure | $1.25亿 | $2.17亿 | -42.7% | $2亿 | $2.5亿 | -20.1% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | – | – | – | $0 | $0 | – |
| Capital Expenditures Incurred but Not yet Paid | -$220万 | $49.3万 | -545.6% | $241万 | $9.2万 | +2,517.4% |
| Capitalized Computer Software, Amortization | – | – | – | $290万 | $260万 | +11.5% |
| Capitalized Computer Software, Net | $320万2025-09-30 | $520万 | -38.5% | $320万 | $520万 | -38.5% |
| Cash and Cash Equivalents, at Carrying Value | $1.17亿 | $2.01亿 | -41.7% | $1.83亿 | $2.26亿 | -19.1% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1.2亿 | $2.04亿 | -41.4% | $1.85亿 | $2.29亿 | -19.1% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$529万 | -$904万 | +41.5% | -$4370万 | -$6010万 | +27.3% |
| Commodity Contract Asset, Current | $619万 | – | – | – | – | – |
| Common Stock, Capital Shares Reserved for Future Issuance | 86.1万 | 79.5万 | +8.3% | 71.6万 | 61.1万 | +17.2% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 2亿 | 2亿 | 0.0% | 2亿 | 1亿 | +100.0% |
| Common Stock, Shares, Issued | 6270万 | 6020万 | +4.2% | 6060万 | 5890万 | +3.0% |
| Common Stock, Shares, Outstanding | 6270万 | 6020万 | +4.2% | 6060万 | 5890万 | +3.0% |
| Common Stock, Value, Issued | $1000 | $0 | – | $0 | $0 | – |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$3510万 | $2020万 | -273.7% | -$7780万 | -$2.08亿 | +62.7% |
| Contract with Customer, Asset, after Allowance for Credit Loss | $619万 | $104万 | +497.1% | $386万 | $203万 | +89.9% |
| Contract with Customer, Liability | $710万2026-03-31 | $199万 | +256.9% | $688万 | $213万 | +223.0% |
| Contract with Customer, Liability, Current | $647万 | – | – | – | – | – |
| Contract with Customer, Liability, Noncurrent | $567万 | – | – | – | – | – |
| Contract with Customer, Liability, Revenue Recognized | $290万 | $170万 | +70.6% | $140万 | $170万 | -17.6% |
| Cost of Revenue | $5590万 | $4480万 | +24.9% | $1.86亿 | $1.8亿 | +3.3% |
| Costs and Expenses | $1.55亿 | $1.26亿 | +22.6% | $5.13亿 | $5.34亿 | -3.9% |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Foreign Tax Expense (Benefit) | – | – | – | $69.2万 | $54万 | +28.1% |
| Current Income Tax Expense (Benefit) | – | – | – | $71.9万 | $56万 | +28.4% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $2.7万 | $2万 | +35.0% |
| Debt Conversion, Converted Instrument, Amount | – | – | – | $0 | $0 | – |
| Debt Securities, Available-for-sale | $4940万 | $4940万 | 0.0% | $4940万 | $5010万 | -1.4% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $2000 | $0 | – | $6.9万 | $11.9万 | -42.0% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $4.1万 | $2000 | +1,950.0% | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $4940万 | $4940万 | 0.0% | $4930万 | $5000万 | -1.3% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Revenue, Current | $647万 | $632万 | +2.2% | $688万 | $213万 | +223.0% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Tax Assets, Gross | $3.99亿2025-09-30 | $3.79亿 | +5.3% | $3.99亿 | $3.79亿 | +5.3% |
| Deferred Tax Assets, Net | $02025-09-30 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Net of Valuation Allowance | $1540万2025-09-30 | $1820万 | -15.5% | $1540万 | $1820万 | -15.5% |
| Deferred Tax Assets, Operating Loss Carryforwards | $2.32亿2025-09-30 | $2.27亿 | +2.4% | $2.32亿 | $2.27亿 | +2.4% |
| Deferred Tax Assets, Other | $1230万2025-09-30 | $1430万 | -13.8% | $1230万 | $1430万 | -13.8% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $6760万2025-09-30 | $5960万 | +13.5% | $6760万 | $5960万 | +13.5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $1340万2025-09-30 | $1340万 | -0.2% | $1340万 | $1340万 | -0.2% |
| Deferred Tax Assets, Valuation Allowance | $3.83亿2025-09-30 | $3.61亿 | +6.3% | $3.83亿 | $3.61亿 | +6.3% |
| Deferred Tax Liabilities, Gross | $1540万2025-09-30 | $1820万 | -15.5% | $1540万 | $1820万 | -15.5% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02